Astrazeneca Plc Share Price (NASDAQ: AZN)

$79.64

▲

-1.33

(-1.64%)

Last updated on August 26, 2025 at 1:29 AM IST

$₹

Check the interactive Astrazeneca Plc Stock chart to analyse performance

Astrazeneca Plc stock performance

as on August 26, 2025 at 1:29 AM IST

Today's Low:$79.50
Today's High:$81.28
$79.64
0.18%
Downside
Day's Volatility :2.19%
Upside
2.02%
52 Weeks Low:$61.24
52 Weeks High:$87.68
$79.64
23.1%
Downside
52 Weeks Volatility :30.15%
Upside
9.16%

Astrazeneca Plc Stock Returns

Period	Astrazeneca Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	12.23%	6.0%	0.0%
6 Months	7.39%	-6.5%	0.0%
1 Year	-8.06%	-11.1%	0.0%
3 Years	23.0%	8.5%	-6.9%

Astrazeneca Plc Key Stats

Check Astrazeneca Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$80.97
Open	$81.36
Today's High	$81.28
Today's Low	$79.5
Market Capitalization	$251.5B
Today's Volume	$3.6M
52 Week High	$87.675
52 Week Low	$61.24
Revenue TTM	$56.5B
EBITDA	$19.1B
Earnings Per Share (EPS)	$2.66
PE Ratio	30.44
Dividend Yield	1.93%
Profit Margin	14.68%
Quarterly Earnings Growth YOY	0.28%
Return On Equity TTM	19.67%

Stock Returns calculator for Astrazeneca Plc Stock including INR - Dollar returns

The Astrazeneca Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Astrazeneca Plc investment value today

Current value as on today

₹96,352

Returns

₹3,648

(-3.65%)

Returns from Astrazeneca Plc Stock

₹8,058 (-8.06%)

Dollar Returns*

₹4,410 (+4.41%)

Indian investors sentiment towards Astrazeneca Plc Stock

-5.61%

Period: Jul 26, 2025 to Aug 25, 2025. Change in 30 Days versus previous period

Investment in Astrazeneca Plc Shares from India has dropped by -5.61% over the past 30 days, indicating reduced transactional activity.

15%

Period: Jul 26, 2025 to Aug 25, 2025. Change in 30 Days versus previous period

Search interest for Astrazeneca Plc Stock from India on INDmoney has increased by 15% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Astrazeneca Plc Stock

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	8484	-94.17	0.25%

Global Institutional Holdings in Astrazeneca Plc

Name
Holdings %
Name
Holdings %
T. Rowe Price Associates, Inc.
1.68%
PRIMECAP Management Company
1.33%
Wellington Management Company LLP
1.11%
Bank of America Corp
1.03%
Capital Research & Mgmt Co - Division 3
1.01%
FMR Inc
0.74%

Analyst Recommendation on Astrazeneca Plc Stock

Rating

Trend

Buy

81%Buy

15%Hold

2%Sell

Based on 38 Wall street analysts offering stock ratings for Astrazeneca Plc(by analysts ranked 0 to 5 stars)

Astrazeneca Plc Share Price Target

What analysts predicted

Upside of 8.75%

Target:

$86.61

Current:

$79.64

Astrazeneca Plc share price target is $86.61, a slight Upside of 8.75% compared to current price of $79.64 as per analysts' prediction.

Astrazeneca Plc Stock Insights

Price Movement
In the last 1 month, AZN stock has moved up by 11.4%
Increasing Revenue
Astrazeneca Plc has shown positive revenue growth over the last two quarters, with revenue increasing from $13.58 billion to $14.45 billion. This represents an average increase of 6.0% per quarter.
Decreasing Net Profit
Astrazeneca Plc's net profit has decreased for the last two quarters, falling from $2.91 billion to $2.45 billion. This represents an average decrease of 16.0% in net profit per quarter.
AZN vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 8.9% return, outperforming this stock by 15.4%
Price to Sales
Astrazeneca Plc is currently valued at a Price-to-Sales Ratio of 26.3, meaning investors are willing to pay $26.3 for every $1 of sales the company generates. In contrast, Johnson & Johnson has a much lower Price-to-Sales Ratio of 4.7, indicating that investors only pay $4.7 for every $1 of sales for that company. This suggests that investors have a significantly higher valuation for Astrazeneca based on its sales.

Astrazeneca Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$24.4B	↑ 10.38%
Net Income	$1.3B	↓ 38.05%
Net Profit Margin	5.47%	↓ 4.29%

	FY20	Y/Y Change
Revenue	$26.6B	↑ 9.16%
Net Income	$3.2B	↑ 139.4%
Net Profit Margin	12.01%	↑ 6.54%

	FY21	Y/Y Change
Revenue	$37.4B	↑ 40.58%
Net Income	$112.0M	↓ 96.5%
Net Profit Margin	0.3%	↓ 11.71%

	FY22	Y/Y Change
Revenue	$44.4B	↑ 18.53%
Net Income	$3.3B	↑ 2835.71%
Net Profit Margin	7.41%	↑ 7.11%

	FY23	Y/Y Change
Revenue	$45.8B	↑ 3.29%
Net Income	$6.0B	↑ 81.11%
Net Profit Margin	13.0%	↑ 5.59%

	FY24	Y/Y Change
Revenue	$54.1B	↑ 18.03%
Net Income	$7.0B	↑ 18.14%
Net Profit Margin	13.01%	↑ 0.01%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$12.7B	↑ 5.45%
Net Income	$2.2B	↑ 126.98%
Net Profit Margin	17.19%	↑ 9.21%

	Q2 FY24	Q/Q Change
Revenue	$12.9B	↑ 2.04%
Net Income	$1.9B	↓ 11.56%
Net Profit Margin	14.89%	↓ 2.3%

	Q3 FY24	Q/Q Change
Revenue	$13.6B	↑ 4.85%
Net Income	$1.4B	↓ 25.84%
Net Profit Margin	10.53%	↓ 4.36%

	Q4 FY24	Q/Q Change
Revenue	$14.9B	↑ 9.78%
Net Income	$1.5B	↑ 4.97%
Net Profit Margin	10.07%	↓ 0.46%

	Q1 FY25	Q/Q Change
Revenue	$13.6B	↓ 8.75%
Net Income	$2.9B	↑ 94.4%
Net Profit Margin	21.46%	↑ 11.39%

	Q2 FY25	Q/Q Change
Revenue	$14.5B	↑ 6.4%
Net Income	$2.5B	↓ 15.98%
Net Profit Margin	16.95%	↓ 4.51%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$19.5B	↑ 13.46%

	FY20	Y/Y Change
Profit	$21.3B	↑ 9.53%

	FY21	Y/Y Change
Profit	$25.0B	↑ 17.18%

	FY22	Y/Y Change
Profit	$32.0B	↑ 27.94%

	FY23	Y/Y Change
Profit	$37.8B	↑ 18.18%

	FY24	Y/Y Change
Profit	$43.9B	↑ 16.14%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$10.5B	↑ 7.67%

	Q2 FY24	Q/Q Change
Profit	$10.8B	↑ 2.81%

	Q3 FY24	Q/Q Change
Profit	$10.5B	↓ 2.52%

	Q4 FY24	Q/Q Change
Profit	$12.2B	↑ 16.04%

	Q1 FY25	Q/Q Change
Profit	$11.4B	↓ 6.67%

	Q2 FY25	Q/Q Change
Profit	$12.0B	↑ 5.54%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$3.0B	↑ 13.41%
Investing Cash Flow	$-657.0M	↓ 168.22%
Financing Cash Flow	$-1.8B	↓ 13.65%

	FY20	Y/Y Change
Operating Cash Flow	$4.8B	↑ 61.64%
Investing Cash Flow	$-285.0M	↓ 56.62%
Financing Cash Flow	$-2.2B	↑ 24.82%

	FY21	Y/Y Change
Operating Cash Flow	$6.0B	↑ 24.26%
Investing Cash Flow	$-11.1B	↑ 3780.0%
Financing Cash Flow	$3.6B	↓ 265.64%

	FY22	Y/Y Change
Operating Cash Flow	$9.8B	↑ 64.48%
Investing Cash Flow	$-3.0B	↓ 73.23%
Financing Cash Flow	$-6.8B	↓ 286.98%

	FY23	Y/Y Change
Operating Cash Flow	$10.3B	↑ 5.48%
Investing Cash Flow	$-4.1B	↑ 37.3%
Financing Cash Flow	$-6.6B	↓ 3.75%

	FY24	Y/Y Change
Operating Cash Flow	$11.9B	↑ 14.65%
Investing Cash Flow	$-8.0B	↑ 96.36%
Financing Cash Flow	$-4.0B	↓ 39.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.5B	↑ 4.45%
Investing Cash Flow	$-2.4B	↑ 124.05%
Financing Cash Flow	$2.0B	↓ 796.91%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$3.1B	↑ 24.09%
Investing Cash Flow	$-2.9B	↑ 19.02%
Financing Cash Flow	$-1.2B	↓ 160.26%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.4B	↑ 9.66%
Investing Cash Flow	$-1.5B	↓ 47.28%
Financing Cash Flow	$-4.1B	↑ 238.05%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.9B	↓ 14.07%
Investing Cash Flow	$-1.2B	↓ 21.99%
Financing Cash Flow	$-671.0M	↓ 83.76%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$3.7B	↑ 27.73%
Investing Cash Flow	$-1.3B	↑ 6.1%
Financing Cash Flow	$-2.7B	↑ 303.43%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$3.4B	↓ 8.81%
Investing Cash Flow	$-2.1B	↑ 68.24%
Financing Cash Flow	$518.0M	↓ 119.14%

Astrazeneca Plc Technicals Summary

Sell

Neutral

Buy

Astrazeneca Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Astrazeneca Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Astrazeneca Plc	10.87%	7.39%	-8.06%	23.0%	41.94%
Eli Lilly And Company	-11.93%	-21.08%	-25.13%	129.46%	377.73%
Johnson & Johnson	7.86%	7.95%	8.92%	9.99%	17.2%
Merck & Co. Inc.	3.94%	-4.44%	-24.86%	-0.25%	1.81%
Novo Nordisk A/s	-17.42%	-37.35%	-57.89%	6.07%	71.99%
Abbvie Inc	11.71%	3.16%	6.67%	55.18%	123.33%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Astrazeneca Plc	30.44	30.44	1.03	4.56	0.2	0.08	0.02	28.85
Eli Lilly And Company	46.36	46.36	1.02	22.86	0.86	0.17	0.01	20.38
Johnson & Johnson	19.2	19.2	1.09	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	13.46	13.46	0.86	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.65	14.65	1.68	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	99.81	99.81	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Astrazeneca Plc	Buy	$251.5B	41.94%	30.44	14.68%
Eli Lilly And Company	Buy	$636.3B	377.73%	46.36	25.91%
Johnson & Johnson	Buy	$431.8B	17.2%	19.2	25.0%
Merck & Co. Inc.	Buy	$218.2B	1.81%	13.46	25.79%
Novo Nordisk A/s	Buy	$247.0B	71.99%	14.65	35.61%
Abbvie Inc	Buy	$372.0B	123.33%	99.81	6.45%

Astrazeneca Plc Dividend announcements

Astrazeneca Plc Dividends September, 2025
In the quarter ending September,2025. Astrazeneca Plc has declared dividend of $0.52

About Astrazeneca Plc

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca Plc has a market cap of $270.68 Billion. It has a P.E ratio of 42.04. The shares of Astrazeneca Plc are trading at $80.97. .

Organization	Astrazeneca Plc
Employees	94300
CEO	Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Industry	Health Technology

Key Management of Astrazeneca Plc

Name	Title
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.	CEO & Executive Director
Dr. Aradhana Sarin M.D.	CFO & Executive Director
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett	Head of Investor Relations
Mr. Jeffrey Pott J.D.	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology R&D
Ms. Iskra Reic	Executive Vice President of International
Mr. David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit
Ms. Ruth March	Senior VP of Precision Medicine - R&D Oncology

Important FAQs about investing in AZN Stock from India :

What is Astrazeneca Plc share price today?

Astrazeneca Plc share price today is $79.64 as on August 26, 2025 at 1:29 AM IST at the close of the market. Astrazeneca Plc share today touched a day high of $81.28 and a low of $79.50.

What is the 52 week high and 52 week low for Astrazeneca Plc share?

Astrazeneca Plc share touched a 52 week high of $87.68 and a 52 week low of $61.24. Astrazeneca Plc stock price today i.e. August 26, 2025 at 1:29 AM IST is closed at $79.64, lower by 9.16% versus the 52 week high.

How to invest in Astrazeneca Plc Stock (AZN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Astrazeneca Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Astrazeneca Plc Shares that will get you 0.0188 shares as per Astrazeneca Plc share price of $79.64 per share as on August 26, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Astrazeneca Plc Stock (AZN) from India?

Indian investors can start investing in Astrazeneca Plc (AZN) shares with as little as ₹87.554 or $1 (as of August 26, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.54 in Astrazeneca Plc stock (as per the Rupee-Dollar exchange rate as on August 26, 2025). Based on Astrazeneca Plc share’s latest price of $79.64 as on August 26, 2025 at 1:29 AM IST, you will get 0.1256 shares of Astrazeneca Plc. Learn more about fractional shares .

What are the returns that Astrazeneca Plc has given to Indian investors in the last 5 years?

Astrazeneca Plc stock has given 41.94% share price returns and 18.05% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?